Table 2.

Efficacy at 6 Months (N = 69)

Status	No.	%
Progression free	54	84
Complete response	7	11
Partial response	31	48
Stable disease	16	25
Progression of disease	10	16

NOTE. In all, 64 patients were eligible for 6-month progression-free survival assessment. Five patients did not have scans at the 6-month time point: two came onto and off the study on the same day because of paclitaxel hypersensitivity; one came off the study and two were lost to follow-up before the 6-month time point and did not have imaging studies.